ArticleThe American journal of psychiatry2024
Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement.
Abstract read
In one paragraph
Article in The American journal of psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data.Addiction (Abingdon, England) · 2025Trial
- Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths.JAMA network open · 2026Article
- Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- Buprenorphine Dispensing Following Medicaid Expansion Amid Unwinding in North Carolina.JAMA network open · 2025Article
- Medicaid Unwinding and Changes in Buprenorphine Dispensing.JAMA network open · 2025Article
- Buprenorphine discontinuation and utilization of psychosocial services: a national study in the Veterans Health Administration.Addiction science & clinical practice · 2025Article
- Associations between COVID impact domains and time to buprenorphine treatment disengagement.The American journal of drug and alcohol abuse · 2025Article
- Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient- and prescriber-level characteristics in Massachusetts, USA.Addiction (Abingdon, England) · 2025Observational
- Organization of primary care and early MOUD discontinuation.Addiction science & clinical practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Arthur Robin WilliamsDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Christine M MauroDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Ben HuberDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Lisa ChiodoDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Stephen CrystalDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Hillary SamplesDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Mark OlfsonDepartment of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
Funding
New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9MCenter for Education and Research on Mental Health TherapeuticsU19HS021112 · AHRQ · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2011 to 2015
$3.9MImproving MOUD Access, Opioid-Related Outcomes and Equity Among Medicare Beneficiaries with DisabilityR01DA057568 · NIDA · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Stephen Crystal · 2022 to 2026
$3.7MOpioid Overdoses among Medicaid Beneficiaries: Predictors, Outcomes, and State Policy EffectsR01DA047347 · NIDA · RUTGERS, THE STATE UNIV OF N.J. · PI CRYSTAL, STEPHEN · 2019 to 2022
$3.1MThe Cascade of Care for Medicaid-Enrolled Youth with Opioid Use DisorderR01DA057566 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI Scott Evan Hadland, Arthur R Williams · 2022 to 2026
$2.9MImproving the treatment cascade of MAT initiation and retention for opioid use disorderK23DA044342 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI WILLIAMS, ARTHUR R · 2017 to 2021
$981kMulti-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatalityK01DA049950 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI SAMPLES, HILLARY · 2020 to 2024
$981kThe OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid UseR01DA059042 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI WILLIAMS, ARTHUR R · 2023 to 2023
$711kAHRQ HHS U19 HS021112NCATS NIH HHS UL1 TR003017NIDA NIH HHS K01 DA049950NIDA NIH HHS K23 DA044342NIDA NIH HHS R01 DA047347NIDA NIH HHS R01 DA057566NIDA NIH HHS R01 DA057568NIDA NIH HHS R01 DA059042
Abstract
PubMed holds no abstract for this paper.
Indexed as
BuprenorphineOpiate Substitution TreatmentOpioid-Related DisordersHumansNarcotic AntagonistsBuprenorphineNarcotic Antagonistsbuprenorphinediscontinuationmedication for opioid use disorderopioid use disorderpharmacoepidemiology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.